Quince Therapeutics, INC Schedule 13G passive stakes

Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 9.0% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, have reported a 0.00% beneficial ownership of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 9.99% beneficial ownership in Quince Therapeutics, Inc., primarily through convertible securities.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 9.99% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Squadron Master Fund LP, along with its investment advisor Squadron Capital Management LLC and key individuals, has reported beneficial ownership of 5.6% of Quince Therapeutics, Inc. common stock.

Millennium Management LLC and affiliated entities have reported a significant beneficial ownership stake of 7.2% in Quince Therapeutics, Inc.

Nantahala Capital Management, LLC and its principals have reported a 7.52% beneficial ownership stake in Quince Therapeutics, Inc. as of March 31, 2026.

Group One Trading LLC has reported a passive 10.67% beneficial ownership stake in Quince Therapeutics, Inc., primarily through common stock and options.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Quince Therapeutics, Inc., including exercisable warrants.

Genextra S.p.A., Francesco Micheli, and Matteo Bruno Renzulli have reported 0% beneficial ownership in Quince Therapeutics, Inc., indicating a full divestment of their previously held stake.

Nantahala Capital Management, LLC and its managing members disclosed a 9.99% beneficial ownership stake in Quince Therapeutics, Inc. common stock.

Sofinnova Capital VIII and its affiliates have filed an amended Schedule 13G, reporting a 2.7% beneficial ownership stake in Quince Therapeutics, Inc. as of March 31, 2025.

Genextra S.p.A., along with its CEO Francesco Micheli and attorney-in-fact Matteo Bruno Renzulli, has disclosed a beneficial ownership of 6.49% in Quince Therapeutics, Inc. common stock.

Sofinnova Capital VIII and its affiliates have disclosed a 5.4% beneficial ownership stake in Quince Therapeutics, Inc. as of December 31, 2024, according to a recent Schedule 13G filing.